Mark W. Parrish
Known title: DirectorCIK: 0001236452
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Transaction History
| OMCL | ▲ Buy | Grant | 4,845 | $0 | 6/1/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 23,660 | $0 | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 1,175 | $0 | 3/6/2026 | View on chart |
| OMCL | ▲ Buy | Grant | 6,828 | $0 | 6/1/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 18,204 | $0 | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 773 | $0 | 3/4/2025 | View on chart |
| OMCL | ▼ Sell | Open Market | 12,000 | $568K | 12/10/2024 | View on chart |
| OMCL | ▲ Buy | Grant | 6,143 | $0 | 5/21/2024 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 17,970 | $0 | 3/3/2024 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 885 | $0 | 3/3/2024 | View on chart |
| OMCL | ▲ Buy | Grant | 115 | $0 | 8/10/2023 | View on chart |
| OMCL | ▲ Buy | Grant | 2,710 | $0 | 5/23/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 19,608 | $0 | 3/4/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 705 | $0 | 3/4/2023 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 3,000 | $45K | 12/28/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 3,000 | $45K | 12/22/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 3,000 | $45K | 12/15/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 3,000 | $45K | 12/7/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 1,278 | $19K | 11/29/2022 | View on chart |
| OMCL | ▲ Buy | Grant | 1,623 | $0 | 5/24/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 2,000 | $30K | 4/6/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 2,000 | $30K | 3/25/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 166 | $0 | 3/21/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 2,000 | $30K | 3/10/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 13,996 | $0 | 3/2/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 335 | $0 | 3/2/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 3,000 | $45K | 2/18/2022 | View on chart |
| OMCL | ▲ Buy | Option Exercise | 3,000 | $0 | 2/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Omnicell Set to Release Q3 2026 Results; Guidance Update
Omnicell will publish its third‑quarter 2026 earnings on Oct. 29, 2026. Analysts noted the company beat revenue expectations but issued weaker EBITDA guidance, which may affect the bullish outlook. The stock is currently near its 12‑touch support level of $42.89 and trades below the average analyst target of $57.86.
Omnicell Set to Release Q3 2026 Results; Guidance Update. Omnicell will publish its third‑quarter 2026 earnings on Oct. 29, 2026. Analysts noted the company beat revenue expectations but issued weaker EBITDA guidance, which may affect the bullish outlook. The stock is currently near its 12‑touch support level of $42.89 and trades below the average analyst target of $57.86.